Business
Phreesia provides healthcare organizations with patient intake, payments, clinical support and engagement software.
Phreesia paired double-digit platform growth with strong positive free cash flow, but operating profit remained negative and the AccessOne acquisition raised the integration burden.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 14.0%OK
- Profitability — The company moved from a net loss of $58.527M to net income of $2.306MOK
- Cash flow — Free cash flow grew 186.0% to $67.713M from $23.672MOK
- Margins — Operating margin expanded 1274 bps to -1.41%OK
- Accounting — High growth and cash generation before full profitabilityWatch
- Insiders — 6 purchases and 58 salesOK
Where the revenue comes from
Fiscal 2026, as Phreesia, Inc. reports it. History and quarterly detail are in the app.
- Subscription and related services$219.5M
- Network solutions$139.7M
- Payment solutions$121.5M
Leadership changes
From Phreesia, Inc.'s own filings, the day they're filed.
- Jon Kessler · director · departureeff. 2026-04-06
- Edward L. Cahill Edward · member · departureeff. 2026-02-23
- L. Cahill · member · departureeff. 2026-02-23
Latest filings
- 10-Q · Quarterly report2026-09-03
- 8-K · Company announcement2026-09-02
- 8-K · Company announcement2026-06-24
- 10-Q · Quarterly report2026-05-28
- 8-K · Company announcement2026-05-27
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Phreesia, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.